Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00035828
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
2002-05-06
Brief Title:
A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody ABX-IL8 to Placebo in Patients With Chronic Bronchitis and COPD
Sponsor:
Abgenix
Organization:
Abgenix
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2003-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine if ABX-IL8 will improve shortness of breath
Detailed Description:
Chronic Obstructive Pulmonary Disease COPD is defined as a disease state characterized by the presence of airflow obstruction due to chronic bronchitis or emphysema The airflow obstruction is generally progressive may be accompanied by airway hyper-reactivity and may be partially reversible Inflammation in the lungs is triggered by exposure to inhaled toxic substances that can lead to tissue damage mucous secretion airways narrowing and tissue destruction
Interleukin-8 IL-8 plays a major role in elevating sputum in patients with COPD and may contribute to tissue destruction Therefore the highly specific antibody to IL-8 such as ABX-IL8 may help to reduce mucous production and tissue destruction
Interleukin-8 IL-8 plays a major role in elevating sputum in patients with COPD and may contribute to tissue destruction Therefore the highly specific antibody to IL-8 such as ABX-IL8 may help to reduce mucous production and tissue destruction
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None